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a b s t r a c t
Anthemis austriaca Jacq. flowers are traditionally used to alleviate abdominal pain, hemorrhoids, ovary
diseases and pneumonia. This study aimed to investigate the effects of A. austriaca flowers, which are fre-
quently used in gynecological disorders, on the rat endometriosis model. The rat endometriosis model
was used to evaluate the potential activity of the plant in endometriosis. The dried plant material was
extracted with n-hexane, ethyl acetate (EtOAc), and methanol (MeOH), successively. The obtained
extracts from A. austriaca flowers were applied to the rats. The adhesion scores, endometrial foci areas,
and cytokine levels of the peritoneal fluids were measured on surgical induction of endometriosis in rats.
The adhesion scores, endometriotic volume, and cytokine levels of the peritoneal fluids were reduced in
the EtOAc, MeOH, and buserelin acetate-treated (reference) groups. The MeOH extract reduced the adhe-
sion scores and endometrial foci areas from 3.1 to 1.1 (p < 0.01) and from 86.4 to 40.5 (p < 0.01), respec-
tively and also the MeOH extract reduced tumor necrosis factor (TNF)-a, vascular endothelial growth
factor (VEGF), and interleukin (IL)-6 levels of the peritoneal fluids from 13.7 to 3.8 (p < 0.01), from
28.4 to 16.3 (p < 0.05) and from 50.2 to 24.3 (p < 0.01), respectively. Therefore, isolation studies were con-
ducted on the EtOAc and MeOH extracts. After the MeOH extract was fractionated using RP-18 column,
the obtained subfractions were evaluated again on the endometriosis rat model. Subfractions A and C of
the MeOH extract displayed statistically significant activity on the endometriosis rat model.
Phytochemical investigation resulted in the isolation of 4-b-D-glucopyranosyloxy-6-methyl-2H-
pyran-2-one (1) from Fr. A and quercetin (2), apigenin-7-O-(300-O-acetyl)-b-D-glucopyranoside (3),
apigenin-7-O-(600-O-acetyl)-b-D-glucopyranoside (4), apigenin-7-O-b-D-glucopyranoside (5), quercetin-
7-O-b-D-glucopyranoside (6) from Fr. C. Moreover, b-sitosterol-3-O-b-D-glucopyranoside (7) was
isolated from the EtOAc extract. As a conclusion, the MeOH extract obtained from A. austriaca flowers
contributed to the regression of endometriosis. In addition, flavonoids and sterols of the plant were
detected as the possible compounds responsible for the activity.
 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Anthemis L. (Asteraceae) genus is represented by 52 species in
the Flora of Turkey and 29 of them are endemic to Turkey
(Grierson and Yavin, 1975; Güner, 2000). Flowers of this genus
are used as antiseptic, anti-inflammatory, antibacterial, antispas-
modic, and sedative worldwide (Vaverkova et al., 2001). In tradi-
tional folk medicine, extracts, tinctures, and salves prepared from
this genus are widely used to alleviate pain and irritation, prevent
ulcers, and in therapies for skin injuries, management of cystitis,
and dental afflictions (Mann and Staba, 1986).
A. austriaca is indigenous to Austria, and distributed widely
from Europe to Turkey. This plant is called ‘‘papatya”,
https://doi.org/10.1016/j.jsps.2019.06.002
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‘‘akbabatça” or ‘‘akbasotu” in Turkey, and the flowers of this plant
have been used traditionally for abdominal pain, hemorrhoids, and
pneumonia (Fujita et al., 1995; Honda et al., 1996; Simsek et al.,
2004). The flowers of A. austriaca has also been used as an infusion
in folk medicine against cough and ovary diseases (Kaval et al.,
2014; Tetik et al., 2013; Uysal et al., 2010). Anthemis species have
been reported to possess anti-inflammatory, antimicrobial, antiox-
idant, antiviral, cytotoxic, hepatoprotective, hypoglycemic, and
hypotensive activities (Al-Snafi, 2016; Baltaci et al., 2011;
Barbour et al., 2004; Shahat et al., 2014). A number of compounds
including xerantholide, taraxasterol acetate, taraxasterol, b-
sitosterol, 1a-hydroxyxerantholide, 6a-hydroxyxerantholide,
10a-hydroxy-11b,13-dihydroxerantholide, 8a-hydroxyxeranthe
molide, xeranthemolide, methyl 8a-isobutyryloxy-3-oxo-4,11(13)
-guaiadien-12-oate, methyl 8a-(2-methylbutanoyloxy)-3-oxo-4,1
1(13)-guaiadien-12-oate, and methyl 3,8-dioxo-4,11(13)-guaia
dien-12-oate have been isolated from the aerial parts of A. austriaca
(Staneva et al., 2004).
Endometriosis is defined as the existence of endometrial glands
and stroma outside of the uterine cavity. It is a common benign
gynecologic disorder, affecting approximately 5% of the general
population and 30% or more of infertile women. The accumulation
of immune cells within the peritoneal cavity and endometriotic
lesions has been recognized in women with endometriosis
(Halme et al., 1987; Klein et al., 1994). In patients with
endometriosis, uterine cells migrate or develop abnormally in ecto-
pic sites such as ovaries, bladder, cervix, rectum, neck, upper arm,
and axillary area. Endometriosis affects females during their repro-
ductive years (Oyelowo, 2007). Dysmenorrhea, nonmenstrual pel-
vic pain, and infertility are some of the symptoms of
endometriosis (Redwine, 2006). Combined oral contraceptives, oral
or parenteral progestogens, synthetic steroid derivatives,
gonadotropin-releasing hormone analogues are used for treating
endometriosis (Dmowski, 2003; Holt et al., 2013). However, those
type medicines have severe side effects. For instance, steroids have
androgenic side effects and also GnRH agonists cause signs and
symptoms of hypoestrogenism; hot flashes, vaginal dryness,
decreased libido, and decreased bone density (Holt et al., 2013).
Because of their serious side effects, those type medicines have
led to researchers to the discovery of new drugs with a low side
effect profile that can be used for treating endometriosis.
Therefore, the present study aimed to investigate the effects of
the extracts and fractions obtained from A. austriaca flowers on the
adhesion scores, endometrial implant volumes, and the cytokine
levels of the peritoneal fluids and also determine the compound/
s responsible for the activity (Fig. 1). In the light of these informa-
tions, we expected to regress the adhesion scores, endometrial
implant volumes, and the cytokine levels with the treatments of
the extracts and fractions. Additionally, we aimed to exhibit which
types of compounds responsible for the activity through bioassay-
guided fractionation.
2. Materials and methods
2.1. Plant material
The flowers of A. austriaca were collected from Ankara-Serefli
koçhisar roadside, opposite the Salt Lake in June 2015, and were
identified by Dr. Ufuk Özbek from the Department of Botany, Fac-
ulty of Art and Science, Gazi University, Ankara, Turkey. A voucher
specimen (GUEF3418) was deposited in the Herbarium of the Fac-
ulty of Pharmacy, Gazi University, Ankara, Turkey.
2.2. Preparation of the plant extracts
Shade-dried and powdered flowers of A. austriaca (400 g) were
successively extracted using 2000 mL of n-hexane, ethyl acetate
(EtOAc), and methanol (MeOH) at room temperature for 48 h.
The extracts were filtered and evaporated to dryness under
reduced pressure at 40 C. The yields of n-hexane, EtOAc, and
MeOH extracts were 7.6, 12.5, and 19.6%, respectively.
2.3. Animals
Six-week-old female, non-pregnant, Wistar albino rats (weigh-
ing 200–250 g) were obtained from Laboratory Experimental Ani-
mals, Kobay, Turkey. All animals were hospitalized in accordance
with the Guide for the Care and Use of Laboratory Animals, and
the experiment was approved by the Experimental Animal Ethics
Committee of Kobay (Protocol number: 233). The animals were
housed in polysulfone cages at 21–24 C, 40–45% humidity, and
light-controlled (12-h light/12-h dark) conditions at Laboratory
Animals Breeding and Experimental Research Center, Kobay
(Ankara, Turkey). The animals were maintained on a standard pel-
let diet and water ad libitum during the experimental period. The
rats were quarantined for at least 2 weeks. The estrous cycle was
followed by a daily assessment of vaginal cytology, and rats
exhibiting regular 4- to 5-day estrous cycles were used in this
study.
2.4. Preparation of surgically induced rat endometriosis by uterine
autotransplantation
2.4.1. First operation
The endometriosis rat model was conducted according to the
Vernon andWilson method (Vernon andWilson, 1985). All the rats
Fig. 1. Flowchart of the present study.
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were anesthetized with intramuscular administration of the com-
bination of 1 mL ketamine (50 mg/mL) and 1 mL xylazine
(20 mg/mL). For the experimental procedure, the rats were placed
in a supine position, and iodine was applied to their abdomens for
disinfection. An incision of 3 cm was made using a scalpel blade.
The subcutaneous and muscle layers were separated, and the
abdominal cavity was opened. The right uterine horn was ligated
and resected. A 15-mm piece of the tissue was trimmed using
microscissors. This section was placed in saline, longitudinally
opened and the endometrium layer was separated from the myo-
metrium. The trimmed piece of the endometriumwas transplanted
onto the inner surface of the abdominal wall with the serosal sur-
face apposed and secured, just next to a vessel using USP 4/0 poly-
glactin sutures (Lactasorb PGLA, Orhan Boz, Turkey). The muscle
layers of the abdomen were closed using USP 3/0 polyglactin
sutures (Lactasorb PGLA, Orhan Boz, Turkey).
2.4.2. Second operation
Twenty-eight days after the first operation, another experi-
ment was performed under anesthesia. The endometriotic foci
areas and adhesions were evaluated in the intra-abdominal area.
The areas of the endometrial foci were calculated by measuring
their length, width, and height using a micrometer. For the
calculation of endometriotic volume, the equation p/6  length 
width  height was used (Altintas et al., 2008). Intra-abdominal
adhesions were evaluated according to the Blauer’s scoring sys-
tem (Blauer and Collins, 1988) as follows: 0, no adhesion; 1, thin
adhesions; 2, thick adhesions in one area; 3, widespread thick
adhesions; and 4, adhesions of the internal organs to the abdom-
inal wall. The abdomen was closed using the same procedure. In
order to minimize adhesion formation, 2 mL of saline were
administered into the abdominal cavity before the closing
abdominal wall (Uzunlar et al., 2014).
Fig. 2. Isolated compounds from the active extracts.
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2.4.3. Treatment procedure
Thirty rats were divided randomly into five groups to evaluate
the activities of the extracts, including six rats in each group.
Thirty-six rats were randomly divided into six groups to evaluate
the activities of the fractions. Three days after the second experi-
ment, 0.5% carboxymethylcellulose (control group) and different
polarity extracts (test materials) and the fractions obtained from
MeOH extract were administered orally once a day for 4 weeks.
The estrous cycle was evaluated by daily vaginal cytology during
the experiment. Extracts and fractions were administered to the
rats at the dose of 100 mg/kg. Buserelin acetate (20 mg/rat) was
subcutaneously injected to the rats once a week (Demirel et al.,
2014; Küpeli Akkol et al., 2015). All rats were sacrificed at the
end of the management process. The intra-abdominal adhesions,
endometriotic foci areas and cytokine levels of the peritoneal fluids
were again evaluated and compared using previous findings.
2.5. Techniques for histopathological investigation
Firstly, all endometriotic tissues from the experimental groups
were fixed with 10% formaldehyde. All tissues were detected using
the Thermo Scientific Excelsior (ES) machine. The tissues were
embedded in paraffin wax and blocks were prepared using the
HistoCentre 2 machine. Subsequently, sections of 3.5 mm thickness
were made from paraffin-embedded blocks using a Leica RM2255
microtome. The sections were stained with hematoxylin–eosin
(HE) using the Shandon Varistan machine. Photographs of patho-
logical endometriotic tissues were taken using Nikon Eclipse Ci
with both polarizing attachment and Digital Image analysis sys-
tem, which were then examined under a light microscope using.
In the histopathological analysis, the severity of lesions in the
implants were determined according to the presence of endome-
trial glands (Elgamal et al., 2016).
2.6. Detection of cytokine levels
In the second exploratory laparotomy, peritoneal fluid was col-
lected to detect the tumor necrosis factor (TNF)-a, vascular
endothelial growth factor (VEGF), and interleukin (IL)-6 levels in
rats. TNF-a, VEGF (Cusabio USA; catalog numbers CSB-E11987r
and CSB-E04757r), and IL-6 (Bio Source International, Nivelles,
Belgium; catalog number MBS701221) in the peritoneal fluid were
quantitatively assessed using the commercially available enzyme-
linked immunosorbent assay kits according to the manufacturer’s
instructions. After the animals were sacrificed, peritoneal fluid
was again collected and the aforementioned process was per-
formed. The pre- and post-treatment results were compared and
statistically evaluated.
2.7. Statistical analysis
The results were given as mean ± standard error of the mean (S.
E.M.). The analysis of variance test was used to determine signifi-
cant differences among groups. Statistical analysis was performed
using the GraphPad Prism 6.0. Lilliefors adjusted Kolmogorov-
Smirnov test was used to test whether the variables used in the
study were normally distributed. Statistical differences between
the treated and the control groups were evaluated by ANOVA-
Dunnett’s test and p values less than 0.05 were considered
significant.
2.8. Isolation studies
2.8.1. Isolation procedure for MeOH extract
The MeOH extract of the plant (20 g) was subjected to vacuum
liquid chromatography using RP-18 silica with elution of H2O:
MeOH (100:0, 2 L), (90:10, 1 L), (80:20, 1 L), (70:30, 2 L), (60:40,
2 L), (50:50, 2 L), (40:60, 2 L), (30:70, 2 L), (20:80, 2 L), (10:90,
1 L), (0:100, 1 L) and then acetone (1 L) to obtain 29 fractions.
The resulting fractions were pooled to four fractions (A–D) on
the basis of thin layer chromatography (TLC) profile, developed
by using EtOAc:CHCl3:MeOH:H2O (15:8:4:1) solvent mixture.
Compound 1 was precipitated from Fr. A which is one of the active
fractions. Fr. C, which is the other active fraction, was subjected to
silica column to obtain other pure compounds. Structure elucida-
tion of isolated compounds was achieved by their NMR and mass
data analyses (Fig. 2).
2.8.2. Isolation procedure for EtOAc extract
EtOAc extract of the plant (4 g) was subjected to silica gel col-
umn chromatography using hexanes:CHCl3 (1:1) and (0:1) and
CHCl3:MeOH (19:1) solvent systems to isolate b-sitosterol-3-O-b-
D-glucopyranoside.
Fig. 3. Endometriotic implants after treatment procedure. (A): Control group; (B): MeOH extract treated group; (C): Fr. A treated group; (D) Fr. C treated group; (E): Reference
group (Buserelin acetate).
Table 1
Intraabdominal adhesion scores of the endometriotic implants of extracts and
fractions from MeOH extract prepared from Anthemis austriaca.
Groups Adhesion scores
Pre-treatment Post-treatment FCV
Control 3.2 ± 0.7 3.5 ± 0.6 1.09
n-Hexane extract 2.8 ± 0.7 2.0 ± 0.4 0.71
EtOAc extract 2.9 ± 0.8 1.4 ± 0.5* 0.48
MeOH extract 3.1 ± 0.7 1.1 ± 0.3** 0.35
Reference 3.0 ± 0.8 0.0 ± 0.0*** 0.00
Control 3.5 ± 1.3 3.8 ± 0.8 1.09
Fr. A 2.9 ± 0.7 1.9 ± 0.7* 0.66
Fr. B 3.5 ± 0.8 3.3 ± 1.0 0.94
Fr. C 3.1 ± 0.9 1.0 ± 0.2** 0.32
Fr. D 3.5 ± 0.7 3.3 ± 0.5 0.94
Reference 2.6 ± 0.7 0.0 ± 0.0*** 0.00
S.E.M.: Standard Error of Mean; FCV: Fold Change Value.
Bold and asterisk indicate statistical significance.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
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3. Results
In the present study, the effects of the extracts obtained from A.
austriaca were investigated on surgically-induced endometriosis in
rats by evaluating the adhesion scores, endometrial foci areas and
cytokine levels of the peritoneal fluids. The endometriotic implants
were observed to be in cystic and vascularized formation during
the second operation (Fig. 3). The adhesion scores, mean
endometriotic implant volume values, and cytokine levels of the
test materials are presented in Tables 1 and 2. According to the
Blauer’s scoring system, the adhesion scores of the MeOH, EtOAc
extract–treated and reference groups significantly decreased from
3.1, 2.9, 3.0 to 1.1 (p < 0.01), 1.4 (p < 0.05) and 0.0 (p < 0.001),
respectively (Table 1). The endometriotic implant volumes signifi-
cantly decreased in the reference, MeOH and EtOAc extract–trea-
ted groups from 95.0, 86.4, 83.9 mm3 to 24.5 (p < 0.001), 40.5
Table 2
Peritoneal TNF-a, VEGF and IL-6 levels before and after treatment in all groups.
Material Peritoneal TNF-a level (pg/ml) Peritoneal VEGF level (pg/ml) Peritoneal IL-6 level (pg/ml)
Pre-treatment Post-treatment FCV Pre-treatment Post-treatment FCV Pre-treatment Post-treatment FCV
Control 9.4 ± 3.1 8.9 ± 2.0 0.95 23.8 ± 5.4 26.1 ± 7.2 1.10 51.4 ± 10.2 50.3 ± 8.7 0.98
n-Hexane extract 8.9 ± 2.3 7.6 ± 1.9 0.85 22.8 ± 7.1 20.9 ± 10.1 0.92 58.6 ± 15.2 53.1 ± 14.3 0.91
EtOAc extract 9.5 ± 1.4 5.3 ± 1.4* 0.56 24.1 ± 8.5 15.2 ± 4.7* 0.63 52.7 ± 9.6 42.2 ± 9.0* 0.80
MeOH extract 13.7 ± 4.2 3.8 ± 0.7** 0.28 28.4 ± 7.4 16.3 ± 7.6* 0.57 54.4 ± 14.6 30.1 ± 9.3** 0.55
Reference 9.1 ± 0.9 2.4 ± 0.6*** 0.26 20.1 ± 6.8 9.9 ± 1.5*** 0.49 50.2 ± 11.3 24.3 ± 9.8*** 0.48
Control 9.9 ± 2.6 10.4 ± 3.5 1.05 26.2 ± 6.7 28.2 ± 4.6 1.08 52.7 ± 13.1 55.4 ± 11.8 1.05
Fr. A 9.4 ± 3.5 6.4 ± 2.3 0.68 28.4 ± 8.5 16.1 ± 4.1* 0.57 57.5 ± 13.4 44.7 ± 9.1* 0.78
Fr. B 10.1 ± 2.1 9.7 ± 2.4 0.96 26.6 ± 7.9 26.8 ± 9.3 1.01 58.4 ± 12.6 56.1 ± 11.5 0.96
Fr. C 13.7 ± 3.2 5.7 ± 1.3* 0.42 27.9 ± 6.5 14.8 ± 5.2* 0.53 55.9 ± 9.8 38.0 ± 7.4** 0.68
Fr. D 12.6 ± 5.4 13.9 ± 5.2 1.10 22.3 ± 9.6 21.8 ± 8.1 0.98 50.1 ± 10.4 52.4 ± 8.5 1.05
Reference 12.9 ± 4.1 2.0 ± 0.5*** 0.16 25.7 ± 7.8 10.2 ± 0.7*** 0.40 53.6 ± 9.7 20.7 ± 5.6*** 0.39
S.E.M.: Standard Error of Mean; FCV: Fold Change Value.
Bold and asterisk indicate statistical significance.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
* : p < 0.05; ** : p < 0.01; *** : p < 0.001
Fig. 4. Endometriotic implant volumes of all treated groups.
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(p < 0.01), and 60.3 (p < 0.05) mm3, respectively (Fig. 4A). Signifi-
cant differences were detected the peritoneal TNF-a, VEGF, and
IL-6 levels in the MeOH extract–treated and reference groups com-
pared to those of the control group (Table 2). After the MeOH
extract treatment, the levels of TNF-a, VEGF, and IL-6 decreased
from 13.7, 28.4, 54.4 pg/mL to 3.8 (p < 0.01), 16.3 (p < 0.05),
30.1 pg/mL (p < 0.01), respectively. After the EtOAc extract
treatment, the levels of TNF-a, VEGF, and IL-6 significantly
decreased from 9.5, 24.1, 52.7 pg/mL to 5.3 (p < 0.05), 15.2
(p < 0.05), 42.2 pg/mL (p < 0.05), respectively. Furthermore, the
cytokine levels were reduced significantly in the reference group.
After fractionation of the MeOH extract, Frs. A and C showed
significant activity compared to the control group. The adhesion
scores and endometriotic foci areas decreased significantly from
2.9 to 1.9 (p < 0.05) and from 85.4 to 62.2 mm3 (p < 0.05), respec-
tively with the treatment of Fr. A, whereas the adhesion scores
and endometriotic foci areas decreased significantly from 3.1 to
1.0 (p < 0.01) and from 92.9 to 54.4 mm3 (p < 0.01), respectively
with the treatment of Fr. C (Table 1 and Fig. 4B). After the Fr. A
treatment, the levels of TNF-a, VEGF, and IL-6 significantly
decreased from 9.4 to 6.4 (non-significant), from 28.4 to 16.1
(p < 0.05) and from 57.5 to 44.7 pg/mL (p < 0.05), respectively.
After the Fr. C treatment, the levels of TNF-a, VEGF, and IL-6 signif-
icantly decreased from 13.7 to 5.7 (p < 0.05), from 27.9 to 14.8
(p < 0.05) and from 55.9 to 38.0 pg/mL (p < 0.01), respectively
(Table 2). In addition, there was not seen any side effect or patho-
logical change in the animals.
The structures of isolated compounds were elucidated by their
NMR and mass data. The molecular ion peak of compound 1 in pos-
itive ion mode was m/z = 289.0909 showing the molecular formula
C12H17O8. According to the NMR (Table 3) and mass data, com-
pound 1 was identified as a 4-b-D-glucopyranosyloxy-6-methyl-
2H-pyran-2-one (Gafner et al., 1998). The molecular ion peak of
compound 2 in positive ion mode was m/z = 303.0523 showing
the molecular formula C15H11O7. According to the NMR (Table 4)
and mass data, compound 2 was identified as a quercetin
(Kyriakou et al., 2012). The molecular ion peak of compound 3 in
positive ion mode was m/z = 475.1245 showing the molecular for-
mula C23H23O11. According to the NMR (Table 4) and mass data,
compound 3 was identified as a apigenin-7-O-(300-O-asetil)-b-D-
glucopyranoside (Xie et al., 2014). The molecular ion peak of com-
pound 4 in positive ion mode was m/z = 475.1208 showing the
molecular formula C23H23O11. According to the NMR (Table 4)
and mass data, compound 4 was identified as a apigenin-7-O-(600-
O-asetil)-b-D-glucopyranoside (Svehlikova et al., 2004). The molec-
ular ion peak of compound 5 in positive ion mode was m/
z = 433.1129 showing the molecular formula C21H21O10. According
to the NMR (Table 5) and mass data, compound 5 was identified as
a apigenin-7-O-b-D-glucopyranoside (Li et al., 2009a). The molecu-
lar ion peak of compound 6 in positive ion mode was m/
z = 465.1094 showing the molecular formula C21H21O12. According
to the NMR (Table 5) and mass data, compound 6 was identified as
a quercetin-7-O-b-D-glucopyranoside (Legault et al., 2011).
According to the NMR data (Table 6), compound 7 was identified
as a b-sitosterol-3-O-b-D-glucopyranoside (Rai et al., 2006).
Table 3
1H and 13C NMR data of compound 1 (CD3OD, 1H: 400 MHz, 13C: 100 MHz).
C/H dC (ppm) dH (ppm)/J
2 (C@O) 167.5 q
3 (CH) 91.7 5.69 (1H, d, J = 2.1 Hz)
4 (C) 171.5 q
5 (CH) 101.5 6.13 (1H, d, J = 2.1 Hz)
6 (C) 164.8 q
7 (CH3) 19.7 2.25 (3H, s)
100 (CH) 100.8 5.04 (1H, d, J = 7.3 Hz)
200 (CH) 77.6 3.49 (1H, m)
300 (CH) 74.3 3.44 (1H, m)
400 (CH) 70.9 3.38 (1H, m)
500 (CH) 78.5 3.49 (1H, m)
600A (CH2) 62.2 3.88 (1H, dd, J = 12.1; 2.2 Hz)
600B (CH2) 62.2 3.69 (1H, dd, J = 12.1; 5.5 Hz)
q: quaterner.
Table 4
1H and 13C NMR data of compound 2, 3, and 4.
2 (CD3OD, 1H: 500 MHz, 13C: 125 MHz) 3 (CD3OD, 1H: 400 MHz, 13C: 100 MHz) 4 (CD3OD, 1H: 400 MHz, 13C: 100 MHz)
C/H dC (ppm) dH (ppm)/J dC (ppm) dH (ppm)/J dC (ppm) dH (ppm)/J
2 (C) 147.9 q 166.5 q 166.8 q
3 (CH) 137.3 q 104.1 6.65 (1H, s) 104.1 6.63 (1H, s)
4 (C@O) 177.3 q 183.6 q 184.0 q
5 (C) 162.5 q 163.4 q 162.9 q
6 (CH) 99.2 6.17 (1H, d, J = 2.0 Hz) 101.2 6.48 (1H, d, J = 2.1 Hz) 101.1 6.48 (1H, d, J = 2.1 Hz)
7 (C) 165.6 q 164.2 q 164.6 q
8 (CH) 94.4 6.38 (1H, d, J = 2.0 Hz) 96.1 6.81 (1H, d, J = 2.1 Hz) 96.2 6.75 (1H, d, J = 2.1 Hz)
9 (C) 158.2 q 158.7 q 158.8 q
10 (C) 104.5 q 107.2 q 107.1 q
10 (C) 124.1 q 123.0 q 122.9 q
20 (CH) 115.9 7.73 (1H, d, J = 2.0 Hz) 129.6 7.87 (2H, d, J = 7.5 Hz) 129.6 7.85 (2H, d, J = 8.9 Hz)
30 (CH) 146.2 q 117.1 6.92 (2H, d, J = 7.5 Hz) 117.1 6.92 (2H, d, J = 8.9 Hz)
40 (C) 148.8 q 162.8 q 163.1 q
50 (CH) 116.2 6.88 (1H, d, J = 8.4 Hz) 117.1 6.92 (2H, d, J = 7.5 Hz) 117.1 6.92 (2H, d, J = 8.9 Hz)
60 (CH) 121.6 7.63 (1H, dd, J = 8.4; 2.0 Hz) 129.6 7.87 (2H, d, J = 7.5 Hz) 129.6 7.85 (2H, d, J = 8.9 Hz)
100 (CH) 101.3 5.18 (1H, d, J = 7.9 Hz) 101.5 5.04 (1H, d, J = 7.4 Hz)
200 (CH) 73.0 3.63 (1H, m) 74.7 3.50 (1H, m)
300 (CH) 78.7 5.09 (1H, m) 77.7 3.51 (1H, m)
400 (CH) 69.4 3.59 (1H, m) 71.6 3.39 (1H, m)
500 (CH) 78.1 3.64 (1H, m) 75.6 3.77 (1H, m)
600A (CH2) 62.1 3.94 (1H, dd, J = 12.0; 2.1 Hz) 64.8 4.46 (1H, dd, J = 11.9; 2.1 Hz)
600B (CH2) 62.1 3.75 (1H, dd, J = 12.0; 4.2 Hz) 64.8 3.49 (1H, dd, J = 11.9; 4.7 Hz)
Acetyl
C@O 172.5 q 172.7 q
CH3 21.1 2.15 (3H, s) 20.8 2.06 (3H, s)
q: quaterner, d: doublet, m: multiplet, s: singlet.
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In the histopathological analyses, whereas a number of
endometrial glands and mononuclear cell infiltration (MCI) were
observed in the control groups, the decrease in endometrial glands
and MCI was detected in the reference, MeOH extract, Frs. A and C
treated groups (Figs. 5 and 6). Endometriotic implants reveal spe-
cial histological characteristics. Mononuclear cell infiltration
occurrs into subjacent fibromuscular tissue along the loose connec-
tive tissue septa in endometriosis. Hyperplasia of the fibromuscu-
lar tissue around the implant is generally observed and
perivascular mononuclear inflammatory cells are usually present
(Cornillie et al., 1990). Histopathological findings showed that
the severity of lesions for the extracts was reduced in the n-
hexane, EtOAc, MeOH, and reference groups, respectively (Fig. 5)
on the other hand the severity of the lesions for the fractions
was reduced subjectively in the Fr. D, Fr. B, Fr. A, Fr. C, and refer-
ence groups, respectively (Fig. 6). The results are presented with
microscopical figures.
4. Discussion
Anthemis genus has diverse biological effects including antimi-
crobial, antioxidant, antiviral, cytotoxic, (Barbour et al., 2004;
Shahat et al., 2014) and phytochemical content including
sesquiterpene lactones, enzymes, sterols, essential oils, and flavo-
noids (Saroglou et al., 2010; Staneva et al., 2008; Theodori et al.,
2006). The flowers of A. austriaca has been used as an infusion in
folk medicine against cough and ovary diseases (Kaval et al.,
2014; Tetik et al., 2013; Uysal et al., 2010). Based on its folkloric
usage, it has been aimed to determine the effects of A. austriaca
on the treatment of endometriosis in this study.
This study investigated the activity of A. austriaca flowers on the
rat endometriosis model. The results displayed that the MeOH
extract and Fr. C obtained from the MeOH extract remarkably
decreased the adhesion scores, endometriotic implant volumes and
cytokine levels. Through bioactivity guided fractionation, five flavo-
noids namely quercetin, apigenin-7-O-(300-O-asetil)-b-D-glucopyra
noside, apigenin-7-O-(600-O-asetil)-b-D-glucopyranoside, apigenin-
7-O-b-D-glucopyranoside, quercetin-7-O-b-D-glucopyranoside
were isolated from Fr. C which was the most active fraction.
In studies investigating the connection between endometriosis
and estrogen levels, it has been reported that the increase in estro-
gen levels leads to the growth of endometrial lesions, and the sup-
pression of estrogen levels contribute to the healing of the
Table 5
1H and 13C NMR data of compound 5 and 6.
5 (DMSO, 1H: 400 MHz, 13C: 100 MHz) 6 (CD3OD, 1H: 400 MHz, 13C: 100 MHz)
C/H dC (ppm) dH (ppm)/J dC (ppm) dH (ppm)/J
2 (C) 164.3 q 148.2 q
3 (CH) 103.1 6.86 (1H, s) 136.5 q
4 (C@O) 182.0 q 177.3 q
5 (C) 161.4 q 161.5 q
6 (CH) 99.5 6.44 (1H, d, J = 2.1 Hz) 100.2 6.44 (1H, d, J = 2.0 Hz)
7 (C) 163.0 q 164.4 q
8 (CH) 94.9 6.83 (1H, d, J = 2.1 Hz) 95.5 6.72 (1H, d, J = 2.0 Hz)
9 (C) 157.0 q 156.2 q
10 (C) 105.4 q 105.9 q
10 (C) 121.1 q 124.0 q
20 (CH) 128.6 7.95 (2H, d, J = 8.8 Hz) 116.2 7.75 (1H, d, J = 2.0 Hz)
30 (CH) 116.0 6.94 (2H, d, J = 8.8 Hz) 146.2 q
40 (C) 161.1 q 148.7 q
50 (CH) 116.0 6.94 (2H, d, J = 8.8 Hz) 116.2 6.87 (1H, d, J = 7.8 Hz)
60 (CH) 128.6 7.95 (2H, d, J = 8.8 Hz) 121.9 7.64 (1H, dd, J = 7.8; 2.0 Hz)
100 (CH) 99.5 5.07 (1H, d, J = 7.2 Hz) 101.6 5.07 (1H, d, J = 7.7 Hz)
200 (CH) 73.1 3.44–3.15 74.7 3.56–3.36
300 (CH) 76.5 77.8
400 (CH) 69.6 71.3
500 (CH) 77.2 78.3
600A (CH2) 60.6 3.72 (1H, dd, J = 10.9; 2.8 Hz) 62.4 3.94 (1H, dd, J = 11.8; 1.9 Hz)
600B (CH2) 60.6 3.49 (1H, dd, J = 10.9; 5.6 Hz) 62.4 3.73 (1H, dd, J = 11.8; 5.6 Hz)
q: quaterner, d: doublet.
Table 6
1H and 13C NMR data of compound 7 [CDCl3:CD3OD (1:1), 1H: 400 MHz, 13C:
100 MHz].
C/H dC (ppm) dH (ppm)/J
1 (CH2) 37.9 –
2 (CH2) 30.1 –
3 (CH) 79.6 –
4 (CH2) 40.4 –
5 (C) 141.0 q
6 (CH) 122.5 5.60 (1H, bs)
7 (CH2) 32.5 –
8 (CH) 31.6 –
9 (CH) 50.8 –
10 (C) 37.3 q
11 (CH2) 21.6 –
12 (CH2) 39.2 –
13 (C) 42.9 q
14 (CH) 57.4 –
15 (CH2) 24.8 –
16 (CH2) 28.8 –
17 (CH) 56.7 –
18 (CH3) 12.2 0.93 (3H, s)
19 (CH3) 19.7 1.26 (3H, s)
20 (CH) 36.7 –
21 (CH3) 19.1 1.17 (3H, d, J = 6.3 Hz)
22 (CH2) 34.5 –
23 (CH2) 26.6 –
24 (CH) 46.5 –
25 (CH) 29.7 –
26 (CH3) 19.3 1.05 (3H, d)
27 (CH3) 20.1 1.07 (3H, d)
28 (CH2) 23.6 –
29 (CH3) 12.2 1.09 (3H, t)
10 (CH) 101.8 4.64 (1H, d, J = 7.8 Hz)
20 (CH) 74.2 3.45 (1H, t)
30 (CH) 77.2 3.63 (1H, m)
40 (CH) 70.9 3.62 (1H, m)
50 (CH) 76.7 3.52 (1H, m)
60A (CH2) 62.3 4.10 (1H, dd, J = 12.0; 2.5 Hz)
60B (CH2) 62.3 3.96 (1H, dd, J = 12.0; 5.1 Hz)
q: quaterner, bs: broad singlet, d: doublet, s: singlet, t: triplet, m: multiplet.
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endometrial lesions (Kitawaki et al., 2002). Moreover, a similar
study performed by Bedaiwy et al. found that endometriotic
implants use estrogen to maintain their viability (Bedaiwy et al.,
2017).
Kettel et al. (1996) reported that the increase of endometriotic
implant volumes is stimulated by estrogen and progesterone. In
case of their absence, the symptoms of endometriosis usually
abate. It has been proven that mifepristone which is antiproges-
terogenic agent appears to be effective in improving the symptoms
and contributing regression of endometriosis in the absence of sig-
nificant side effects in the same study (Kettel et al., 1996).
As mentioned before, there is a relation between ovarian ster-
oids such as estrogen and progesterone and endometriosis. Based
on the previous studies, we considered that the extracts and frac-
tions obtained from A. austriaca contributed to the regression of
endometriosis by reducing the levels of estrogen and
progesterone.
Endometriosis causes inflammatory changes in the peritoneal
fluid. For instance, it can give rise to the proliferation of macro-
phages and phagocytic dysfunction and also release proinflamma-
tory and angiogenic factors (Taylor and Lebovic, 2014). Wu and Ho
(2003) reported that in case of endometriosis, the levels of TNF-a,
VEGF, and IL-6 increase whereas the levels of IL-8, IL-13, and
interferon-c do not show any change. IL-6 was reported to be cru-
cial in the regulation of ovarian steroid creation and early implan-































Fig. 5. Histopathological views of all extracts treated groups. (A) Control group; F: fibroblast cells, G: endometrial gland, MCI: monuclear cells infiltration, (B) n-Hexane
extract treated group; C: collagen fibers, F: fibroblast cells, G: endometrial gland, E: endometrial gland epithelium, MCI: monuclear cells infiltration, (C) EtOAc extract treated
group; G: endometrial gland, E: endometrial gland epithelium, C: collagen fibers, F: fibroblast cells, DC: degenerative collagen fibers, (D) MeOH extract treated group; DG:
degenerative endometrial gland, DC: destruction connective tissue, MCI: mononuclear cells infiltration, (E) Buserelin acetate group; DF: degenerative functional layer, DG:
degenerative endometrial gland, DM: degenerative myometrium, C: separation of connective tissue.
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for the infertility in women with endometriosis (Punnonen et al.,
1996). The presence of VEGF has also been verified in human endo-
metrium, and it may be important in both physiological and patho-
logical angiogenesis (McLaren et al., 1996; Shifren et al., 1996).
Oral contraceptives, androgenic agents, progestins, gonadotropin-
releasing hormone (GnRH) analogs are used in the medical treat-
ment of endometriosis (Waller and Shaw, 1993; Valle and
Sciarra, 2003).
Collins-Burow et al. (2000) reported that some flavonoids pos-
sess antiestrogenic activity as well as estrogenic activity. The antie-
strogenic activities of flavonoids such as apigenin, luteolin,
kaempferide are more than their estrogenic activities (Collins-
Burow et al., 2000). Furthermore, flavonoids decrease cytokine
expression and secretion (Leyva-Lopez et al., 2016). Another study
showed that apigenin inhibited TNF-a-induced cell proliferation
and reduced the mitogenic activity and inflammatory response in
endometriotic stromal cells (Suou et al., 2011). Apigenin was sim-
ilarly stated to inhibit proliferation and tumorigenesis of human
ovarian cancer A2780 cells in vitro (Li et al., 2009b) and might be
a substitute compound for treating endometrial cancer and post-
menopausal women (Shukla and Gupta, 2007). In the light of these
informations, the flavonoids especially apigenin derivatives could
be effective by regulating cytokine levels on the endometriosis.
Moreover, in this study, b-sitosterol-3-O-b-D-glucopyranoside
was isolated from the EtOAc extract, which was the second active
extract. Fraile et al. (2012) and Bouic and Lamprecht (1999)
showed that plant sterols, such as b-sitosterol and b-sitosterol-3-
O-b-D-glucopyranoside, have immunomodulating properties.

























Fig. 6. Histopathological views of all fractions obtained from the MeOH extract treated groups. (A) Control group; C: regular collagen fibers, F: fibroblast cells, G: endometrial
gland, MCI: monuclear cells infiltration, (B) Fr. A treated group; DC: degenerative collagen fibers, DG: degenerative endometrial gland, (C) Fr. B treated group; F: fibroblast
cells, G: endometrial gland, C: collagen fibers, E: endometrial gland epithelium, (D) Fr. C treated group; DF: degenerative fuctional layer, DG: degenerative endometrial gland,
DM: degenerative myometrium, DE: degenerative endometrial epithelium, (E) Fr. D treated group; F: fibroblast cells, G: endometrial gland, C: collagen fibers, (F) Buserelin
acetate group; DE: degenerative endometrial epithelium, DG: degenerative endometrial gland.
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At the time of clinical presentation, most women already have
established endometriosis, it is hardly possible to give experimen-
tal evidence for physiological roles in the pathogenesis of this dis-
ease in humans. In addition, ethical considerations limit the
performance of controlled experiments, and it is not possible to
monitor the disease progression without performing repeated
laparoscopies. Thus, research into the fundamental mechanisms
by which menstrual endometrium adheres, invades and estab-
lishes a functional vasculature to persist in an ectopic site, as well
as the development of new therapeutical approaches, is best per-
formed in experimental animal models (Grümmer, 2006). Despite
of these advantages of animal models, they have some limitations
such as small sample size, the applicability to humans.
5. Conclusions
In this study, the effects of A. austriaca flowers were investi-
gated in the rat endometriosis model. According to the biological
activity results, the EtOAc and MeOH extracts of the plant showed
statistically significant activity. However, the activity of the MeOH
extract was higher than that of the EtOAc extract. Phytochemical
studies led to the isolation of 5 flavonoids and 1 lactone from the
MeOH extract and b-sitosterol-3-O-b-D-glucopyranoside from the
EtOAc extract. Therefore, according to the results of the present
study, flavonoids and sterols have been detected as the possible
compounds responsible for the activity. Moreover, there is only
one publication about the phytochemical ingredient of A. austriaca
in the literature (Staneva et al., 2004). So, the presence of isolated
compounds from A. austriaca in the plant has been reported first
time in the present study.
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Peninsula (Turkey). Biol. Divers. Conserv. 3, 15–22.
Uzunlar, O., Ozyer, S., Engin-Ustun, Y., Moraloglu, O., Gulerman, H.C., Caydere, M.,
Keskin, S.M., Mollamahmutoglu, L., 2014. Effects of repeated propranolol
administration in a rat model of surgically induced endometriosis. Eur. J.
Obstet. Gynecol. Reprod. Biol. 182, 167–171.
Valle, R.F., Sciarra, J.J., 2003. Endometriosis: Treatment strategies. Ann. N.Y. Acad.
Sci. 997, 229–239.
Vaverkova, S., Haban, M., Eerna, K., 2001. Qualitative properties of Anthemis
tinctoria and Anthemis nobilis (Chamaemelum nobile) under different
environmental conditions. Ecophysiology of plant production processes in
stress conditions. In: 4th International Conference, Slovakia, pp. 1–2.
Vernon, M.W., Wilson, E.A., 1985. Studies on the surgical induction of endometriosis
in the rat. Fertil. Steril. 44, 684–694.
Waller, K.G., Shaw, R.W., 1993. Gonadotropin-releasing hormone analogues for the
treatment of endometriosis: long-term follow-up. Fertil. Steril. 59 (3), 511–515.
Wu, M.Y., Ho, H.N., 2003. The role of cytokines in endometriosis. Am. J. Reprod.
Immunol. 49, 285–296.
Xie, X.Y., Wang, R., Shi, Y.P., 2014. Flavonoids from the flowers of Matricaria
chamomilla. Chem. Nat. Compd. 50 (5), 910–911.
M. Ilhan et al. / Saudi Pharmaceutical Journal 27 (2019) 889–899 899
